17,060 Shares in Hims & Hers Health, Inc. $HIMS Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 17,060 shares of the company’s stock, valued at approximately $354,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BAM Wealth Management LLC grew its holdings in shares of Hims & Hers Health by 5.6% during the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after purchasing an additional 393 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Hims & Hers Health by 3.1% in the 2nd quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after buying an additional 443 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Cura Wealth Advisors LLC increased its stake in Hims & Hers Health by 8.5% in the fourth quarter. Cura Wealth Advisors LLC now owns 6,512 shares of the company’s stock valued at $211,000 after acquiring an additional 512 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Hims & Hers Health by 1.1% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company’s stock valued at $1,513,000 after purchasing an additional 521 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research note on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, TD Cowen dropped their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $30.70.

Hims & Hers Health Stock Up 0.2%

HIMS stock opened at $32.89 on Monday. The firm has a market capitalization of $7.61 billion, a PE ratio of -365.44, a P/E/G ratio of 92.42 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The stock’s 50 day moving average is $30.14 and its 200-day moving average is $26.34.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period in the previous year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00. Following the transaction, the insider owned 6,790 shares of the company’s stock, valued at $213,885. This trade represents a 39.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells bought 48,400 shares of Hims & Hers Health stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold a total of 83,126 shares of company stock worth $2,711,339 in the last ninety days. 11.76% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.